Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome

Shuang Liu1, Chen Li2, Ming-Wei Tang1, Wen-Shuai Xu3, Ke-Qi Chen3, Xin Sui4, Xin-Lun Tian3, Kai-Feng Xu3

1School of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 10005, China; 2Department of Traditional Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China; 3Department of Respiratory and Critical Care Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China; 4Department of Radiology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China.

To the Editor: Lymphangioleiomyomatosis (LAM) is a rare multi-systemic disease that predominantly affects women and is associated with cystic lung destruction, chylous fluid accumulation, and abdominal tumors.[1] The lung function of LAM patients declines at two to four or more times faster rates than the typical age-related decline. Although the mammalian target of rapamycin (mTOR) inhibitor has shown certain benefits for patients with LAM, treatment options remain limited.[2] Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a spectrum of heterogeneous diseases characterized by osteoarticular and dermatological manifestations. Non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs, bisphosphonates, and intra-articular steroids are frequently prescribed but are often insufficient to control disease progression. Biological agents, which may be administered in refractory cases, have recently shown promising clinical utility. Janus kinase (JAK) and downstream effectors signal transducer of activation (STAT) proteins are important intra-cellular signaling molecules for type I and II cytokines, and recent evidence suggested the efficacy of JAK inhibitors in the treatment of autoimmune diseases.[3] Moreover, tofacitinib, a small-molecule selective JAK inhibitor, showed good efficacy in the treatment of refractory SAPHO syndrome.[4] Here, we presented a patient with SAPHO syndrome complicated with LAM whose arthralgia and pulmonary function both improved after tofacitinib treatment.

A 29-year-old female patient presented with progressive polyarthritis and elevated serum inflammatory parameters in May 2016 and was diagnosed with SAPHO syndrome. Later, enhanced computed tomography (CT) revealed diffusely distributed round, regular, thin-walled cysts in the lung and cystic lesions along the lymphatic vessels in the posterior mediastinum and the retroperitoneal region. The vascular endothelial growth factor D (VEGF-D) was 1776 pg/mL (reference range: <800 pg/mL). She was diagnosed with LAM [Figure 1A] according to the 2017 American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline of LAM.[1] After sequential administration of NSAIDs, glucocorticoids, and interleukin (IL)-6 inhibitors, there was no substantial amelioration of symptomatic, laboratory, or imaging parameters. Inspired by the efficacy observed in other rheumatologic disorders, as well as for a previous SAPHO case, treatment with tofacitinib was considered. Because this JAK inhibitor acts upstream of the mTOR pathway, it is hypothesized that administration of tofacitinib may have some therapeutic effect for LAM. Tofacitinib was tentatively administered at 5 mg orally twice daily. Three weeks later on hospital discharge, the patient reported a marked improvement of symptoms. Inflammatory markers decreased to nearly normal ranges [Figure 1B]. The disease activity index also declined [Figure 1C]. After 16 weeks of tofacitinib treatment, MRI showed obvious amelioration of the bone marrow edema in the sacroiliac and sternoclavicular regions. Regarding LAM, her pulmonary function test showed an obstructive defect over time. Nonetheless, an improvement in the forced expiratory volume in 1 s, forced vital capacity, and diffusing capacity for carbon monoxide (DLCO) was observed after tofacitinib administration [Figure 1D]. The patient tolerated the medicine well and had no adverse effects. Her VEGF-D level remained stable (1931 pg/mL).

Shuang Liu and Chen Li contributed equally to this work.

Correspondence to: Dr. Xin-Lun Tian, Department of Respiratory and Critical Care Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifu Yuan, Wangfujing, Beijing 100730, China
E-Mail: xinlun_t@ sina.com

© 2019 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-NDD), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2019;132(19)
Received: 10-06-2019 Edited by: Xin Chen

| Access this article online | 
|---------------------------|
| Quick Response Code:      |
| Website:                  |
| www.cmj.org              |
| DOI:                      |
| 10.1097/CM9.0000000000000441 |
Our case indicated that a JAK inhibitor may play a therapeutic role in both SAPHO and LAM. The JAK-STAT pathway has a crucial function in intra-cellular signaling of type I and type II cytokines. Therefore, inhibiting JAK will eventually block the action of pathological cytokines.\textsuperscript{[3]} Moreover, as downstream mediators, JAK inhibitors have the potential to exert greater anti-inflammatory activity than do biologics that target only one cytokine. Tofacitinib, which selectively suppresses JAK1 and JAK3, may block signals of several essential cytokines involved in the transcriotion of genes responsible for inflammation and immune regulation. Furthermore, a previous study reported crosstalk between JAK and the phosphoinositide 3-kinase/protein kinase B/mTOR signaling pathway, suggesting a potential therapeuttic benefit of targeting molecules in this pathway.\textsuperscript{[5]}

In the initial stage of the clinical course, the patient lacked respiratory symptoms but showed typical radiological changes and elevated VEGF-D levels. To avoid invasive techniques, histopathological confirmation was not performed. However, the patient was under serial monitoring, and the later reduction in pulmonary function supported the diagnosis of LAM. One major limitation of this case was that lung function indicators might overestimate the therapeutic effect of JAK inhibitors. In the early stage, lung function might be underestimated due to the restriction of thoracic mobility caused by thoracic pain owing to SAPHO syndrome. Regardless, the improvement in DLCO and stabilization of chest CT also supported the benefit of JAK inhibitors for LAM. Common adverse effects of JAK inhibitors include increased risk of infection and myelo-suppression.\textsuperscript{[10]} As for this patient, no obvious toxicity was reported during the 16 weeks of tofacitinib treatment, though its long-term safety still needs further investigation.

In conclusion, this case provided a valuable experience of the clinical utility of tofacitinib in preventing LAM progression and in controlling osteoarticular and cutaneous manifestations of SAPHO syndrome. In the future, clinical trials on a larger scale should be carried out to elucidate the efficacy of JAK inhibitors for LAM and SAPHO syndrome.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that the names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Conflicts of interest**

None.

**References**

1. Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 2017;196:1337–1348. doi: 10.1164/rccm.201709-1965ST.

2. Xu KF, Tian X, Yang Y, Zhang H. Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage. Thorax 2018;73:308–310. doi: 10.1136/thoraxjnl-2017-211135.

3. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843–862. doi: 10.1038/nrd.2017.201.

4. Yang Q, Zhao Y, Li C, Luo Y, Hao W, Zhang W. Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Medicine 2018;97:e11149. doi: 10.1097/md.0000000000011149.

5. Boussof E, Montazeri Alabadi H. Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol 2018;8:287. doi: 10.3389/fonc.2018.00287.

**How to cite this article**: Liu S, Li C, Tang MW, Xu WS, Chen KQ, Su X, Tian XL, Xu KF. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. Chin Med J 2019;132:2378–2379. doi: 10.1097/cm9.000000000000441